Cost-Effectiveness of Perioperative Enfortumab Vedotin and Pembrolizumab for Bladder Cancer. Su ZT, Garman TS, Rivera Lopez CA, Talwar R, et al. JAMA Netw Open 2026;9:e2640370.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Su ZT, Garman TS, Rivera Lopez CA, Talwar R, et al. Cost-Effectiveness of Perioperative Enfortumab Vedotin and Pembrolizumab for Bladder Cancer. JAMA Netw Open 2026;9:e2640370.
PMID: 42900471